Related Experiment Video
Updated: Jul 18, 2026
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Synthetic miR-34a against solid tumours: a predictable failure
Sophie Mockly1,2, Hervé Seitz3
1Institut de Génétique Humaine, UMR 9002 CNRS and university of Montpellier, Montpellier, France.
Abstract:
A prolific scientific literature attributes pro- or anti-oncogenic properties to many human microRNAs ("miRNAs"). While many of these studies are based on unpersuasive analyses, one candidate suppressor tumour miRNA, miR-34a, appeared convincing enough to be administered to human patients in a clinical trial-with disappointing outcomes. Here, we review possible reasons for that failure, and their implications for other miRNAs.
Insights
Many microRNAs (miRNAs) show promise as cancer treatments, but flawed analyses often lead to failure. The miR-34a clinical trial
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are implicated in cancer, with many studied for therapeutic potential.
- miR-34a was identified as a potential tumor suppressor miRNA.
- A clinical trial involving miR-34a yielded disappointing results.
Approach:
- Reviewing scientific literature on miRNA functions in cancer.
- Analyzing the reasons behind the failure of the miR-34a clinical trial.
- Evaluating the implications for future miRNA-based cancer therapies.
Key Points:
- Numerous studies attribute oncogenic or tumor-suppressive roles to miRNAs based on weak evidence.
- The clinical trial of miR-34a, a candidate tumor suppressor miRNA, did not meet expectations.
- Flawed analytical methodologies in preclinical research may explain therapeutic failures.
Conclusions:
- The promising therapeutic potential of miRNAs in oncology requires rigorous validation.
- Re-evaluation of analytical approaches is crucial for advancing miRNA-based cancer treatments.
- Lessons learned from miR-34a failure can guide future miRNA research and clinical applications.
